The mechanism and significance of the difference between verapamil and reserpine to eliminate the side population of A549 and H460 lung cancer cells

CAO Bao-shan,JIA Jun,REN Jun,MA Bo,LU Zhi-hao,DI Li-jun,SONG Guo-hong,FANG Jian,MA Li-wen
DOI: https://doi.org/10.3969/j.issn.1672-4992.2009.01.003
2009-01-01
Journal of Modern Oncology
Abstract:Objective:To evaluate the effects of verapamil or reserpine on side population(SP)from A549 and H460 and explore its mechanisms.Meanwhile to evaluate whether CD133 is regarded as a stem cell marker of lung cancer.Methods:Side population(SP) and non-side population(non-SP) cells from lung cancer cell lines of A549 and H460 were separated by fluorescence-activated cell sorting(FACS).Verapamil or reserpine was used to inhibit efflux of Hoechst 33342 by SP cells.Reverse transcription-polymerase chain reaction(RT-PCR) was employed to analyze the expression of ABCG2,MDR1,CD133 and GAPDH of SP or non-SP subset from A549 and H460.Results:Reserpine was more effective than verapamil in inhibiting efflux of Hoechst33342 by SP cells.At lower concentration,the inhibitors were more effective through preinhibition than coinhibition;ABCG2,MDR1 and CD133 were overexpressive in SP cells of both A549 and H460 compared with non-SP cells.Conclusion:The inhibitors of targeting the function of ABCG2 would be effective to overcome resistance to current chemotherapeutic drugs.CD133 may be a new cancer stem cell surface marker of lung cancer.
What problem does this paper attempt to address?